News

For the sixth consecutive year, Weill Cornell Medicine has been awarded the Health Professions Higher Education Excellence in Diversity (HEED) Award by INSIGHT Into Diversity magazine, which recognizes the institution’s exceptional commitment to diversity and inclusion.

An American Heart Association (AHA) Presidential Advisory, co-authored by a committee including the dean of Weill Cornell Medicine, outlines an ambitious plan to increase rigorous research on initiatives aimed at providing food as medicine for chronic conditions.

Weill Cornell Medicine has been at the forefront of medical education since its inception, with a steadfast commitment to providing the best training for generations of physicians.

Dr. Lisa Newman, chief of the...

A Weill Cornell Medicine researcher has received a $610,000 grant from the Department of Defense to investigate the mechanisms causing DNA instability that potentially drives metastasis in bladder cancer.

Dr. Chenxu Zhu, an assistant professor of physiology and biophysics at Weill Cornell Medicine and a core faculty member of the New York Genome Center, has been awarded the National Institutes of Health Director’s New Innovator Award to fund an ambitious project to develop single-cell sequencing tools, known collectively as “multi-omics,” that will help track age-related changes in gene regulation programs, as well as cell decay, in brain cells from preclinical models. 

Researchers at Weill Cornell Medicine have illuminated one of the important ways that cells respond to stress. The findings could also be relevant to Alzheimer’s, ALS and other diseases in which this mechanism may be abnormally active.

Awards, honors and achievements for the month of September.  

Dr. Vanessa Bellat, an assistant professor of chemistry in radiology and an affiliate of the Molecular Imaging and Innovations Institute (MI3) at Weill Cornell Medicine, has been awarded a $2 million, four-year R37 MERIT grant from the National Cancer Institute, part of the National Institutes of Health. She will be developing a new therapeutic approach using nanofibers that selectively deliver drugs to the lungs to treat metastatic tumors. 

Researchers at Weill Cornell Medicine have discovered that radiation therapy combined with two types of immunotherapy—one that boosts T cells and another that boosts dendritic cells—can control tumors in preclinical models of triple negative breast cancer, a cancer type that’s typically resistant to immunotherapy alone.

Weill Cornell Medicine has received a three-year, nearly $6 million grant to lead one of three national contraceptive research centers.

Craniosynostosis, the premature fusion of the top of the skull in infants, is caused by an abnormal excess of a previously unknown type of bone-forming stem cell, according to a preclinical study led by researchers at Weill Cornell Medicine.

Weill Cornell Medicine has been awarded a five-year, $5 million grant from the United States Department of Health and Human Services through the Office of Population Affairs under the Teen Pregnancy Prevention Program to conduct a randomized trial testing whether a bilingual video game called “No Baby No (No Bebé No)” can increase the use of contraception among sexually active Black and Hispanic adolescents.

The vertebral bones that form the spine are derived from a distinct type of stem cell that secretes a protein favoring tumor metastases, according to a study led by researchers at Weill Cornell Medicine.

The designation adds the academic medical center to NORD’s collaborative network of 40 participating institutions that research and treat rare diseases.

As part of a National Institutes of Health initiative to improve maternal health and pregnancy outcomes nationwide, Weill Cornell Medicine and NewYork-Presbyterian will play a pivotal role as collaborators with Columbia University Irving Medical Center as one of 10 nationwide IMPROVE (Implementing a Maternal Health and Pregnancy Outcomes Vision for Everyone) Maternal Health Research Centers of Excellence. 

Awards, honors and achievements for the month of August. 

Researchers at Weill Cornell Medicine and RMIT University in Australia have discovered that ion channels called BK channels have unique openings in their sides, which drug molecules may be able to access.

A member of an important class of ion channel proteins can transiently rearrange itself into a larger structure with dramatically altered properties, according to a study led by researchers at Weill Cornell Medicine.

An international phase 3 clinical trial, done in participation with Weill Cornell Medicine and NewYork-Presbyterian, found that a new targeted treatment called zolbetuximab, given in combination with a standard chemotherapy, extended survival for patients with advanced gastric or gastroesophageal junction cancer that overexpressed a specific biomarker.